© TAXIS Pharmaceuticals All Rights Reserved
News & Events
TAXIS Pharmaceuticals, Inc. Rutgers, The State University of New Jersey, and the University of Medicine and Dentistry of New Jersey (UMDNJ)
have entered into an exclusive licensing agreement for worldwide rights to develop and commercialize a novel antimicrobial technology addressing multidrug-resistant (MDR) bacterial infections. The alarming rise in the...
Research & Development
TAXIS Pharmaceuticals, accomplished team of medicinal chemists, microbiologists, and biophysicists employ a rational drug design strategy
to the discovery and development of early-stage clinical candidates for the treatment of highly drug-resistant forms of bacterial infections. To date, the team has designed and is in the process of implementing....
Business Development
TAXIS Pharmaceuticals is a virtual company, and will remain so until it is strategically and financially advantageous to significantly expand internal operations.
It is anticipated that this inflection point will be coincident with achievement of proof-of-concept in vivo animal efficacy studies. Since its inception, TAXIS Pharmaceuticals has therefore relied upon partnerships ...